These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg136-->Cys) variant. Feussner G, Albanese M, Valencia A. Atherosclerosis; 1996 Oct 25; 126(2):177-84. PubMed ID: 8902143 [Abstract] [Full Text] [Related]
28. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia. Georgiadou D, Chroni A, Vezeridis A, Zannis VI, Stratikos E. PLoS One; 2011 Oct 25; 6(11):e27037. PubMed ID: 22069485 [Abstract] [Full Text] [Related]
29. Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli. Morrow JA, Arnold KS, Weisgraber KH. Protein Expr Purif; 1999 Jul 25; 16(2):224-30. PubMed ID: 10419818 [Abstract] [Full Text] [Related]
30. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins. Mulder M, van der Boom H, de Knijff P, Braam C, van den Maagdenberg A, Leuven JA, Havekes LM. Atherosclerosis; 1994 Aug 25; 108(2):183-92. PubMed ID: 7980718 [Abstract] [Full Text] [Related]
31. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Huang Y, Rall SC, Mahley RW. Arterioscler Thromb Vasc Biol; 1997 Nov 25; 17(11):2817-24. PubMed ID: 9409260 [Abstract] [Full Text] [Related]
33. Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E. Vogel T, Weisgraber KH, Zeevi MI, Ben-Artzi H, Levanon AZ, Rall SC, Innerarity TL, Hui DY, Taylor JM, Kanner D. Proc Natl Acad Sci U S A; 1985 Dec 25; 82(24):8696-700. PubMed ID: 3909150 [Abstract] [Full Text] [Related]
34. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, Arnold KS, Newhouse YM, Innerarity TL, Weisgraber KH. Nat Struct Biol; 1996 Aug 25; 3(8):718-22. PubMed ID: 8756331 [Abstract] [Full Text] [Related]
35. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. Dong LM, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, Agard DA. J Biol Chem; 1994 Sep 02; 269(35):22358-65. PubMed ID: 8071364 [Abstract] [Full Text] [Related]
38. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Rall SC, Weisgraber KH, Innerarity TL, Mahley RW. Proc Natl Acad Sci U S A; 1982 Aug 02; 79(15):4696-700. PubMed ID: 6289314 [Abstract] [Full Text] [Related]
39. Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. Wardell MR, Brennan SO, Janus ED, Fraser R, Carrell RW. J Clin Invest; 1987 Aug 02; 80(2):483-90. PubMed ID: 3038959 [Abstract] [Full Text] [Related]
40. Familial dysbetalipoproteinemia in three patients with apoE 2*(Arg136-->Cys) gene variant. Vrablík M, Horínek A, Ceska R, Stulc T, Kvasnicka T. Physiol Res; 2003 Aug 02; 52(5):647-50. PubMed ID: 14535841 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]